We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Disperse Tech | LSE:DPT | London | Ordinary Share | GB0001786069 | ORD 1P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.00 | - |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| - |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| - | 0 | GBX |
Disperse Tech (DPT) Share Charts1 Year Disperse Tech Chart |
|
1 Month Disperse Tech Chart |
Intraday Disperse Tech Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 31/5/2005 | 17:58 | Disperse - World-beating Tech on the Cheap | 186 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 11/2/2005 17:49 by tyranosaurus Why has DPT share price disappeared along with the trades etc ??I tried DPG but comes up with "unknown symbol" |
Posted at 30/1/2005 13:43 by rambutan2 right, now im not the best at jotting down notes at agms, but this was the gist/my take.first things first. i got it confirmed that the agreements with shiseido, nu skin, nice-pak, and cosmetic essence etc can be forgotten about. nothing came of them. they are null and void. so, the two historic licences in action are the two the company mentions ie estee and bbw. the former is ticking along nicely but there is no chance of renegotiating it unless their is a change in the way estee want to use the tech, which unlikely. as we know the bbw contract was renegotiated and that kicked in last april (i think?) with the first cheque arriving last week. the new contract is done on net sales, with the first $50m at 1% (sorry missed the increments after that, but it went up to 2% to a certain point, but if it went beyond a certain point then dropped back down.) i jotted down that perhaps $500k to come from bbw this year. the reason the above two licence agreements came to fruition and others didnt was said to be that estee and bbw do their own production while others subcontract it out and so are not necessarily in charge of their own destiny to the same extent. as the dpt tech is essentially 'disruptive' folks do their best to resist it. it was also interesting to hear that time/money has to be spent policing the two licences, so they are not quite the free rev stream that they might appear. of course, the above isnt to say that one of the big cosmetic cos might not have a change of heart one day and decide to go for it. xme can also be written off, at least for the time being. the tech has not sold and a decision is being taken on its future within the next few weeks. so, now we know what we are dealing with on the historic side, and anything new can be seen as a very big bonus. blue sky. so, onto the new model. and here there seemed to be genuine high hopes of success. with talk of turnover targets of £40-£50m within 3yrs. acquisitions are hoped for, but would have to be immediately earnings enhancing. if liz french performs the extra payments (up to £4.5m) will come out of the profits. ie it will pay for itself. the virgin deal brings in much better margins than the estee/bbw licences. there are very high hopes for similar deals with the likes of asda, tesco, boots etc. while on the liz french distribution side, names touted were superdrug, lloyds chemists and co-op. progress here has been a little slower than hoped for as its taken a bit longer to get in the right personel ie the marketing lady cant start until april. everyone seemed v confident of hitting any stated turnover targets. (my notes slightly muddled for the above but im certain ive got the gist) cash management is going to be crucial for dpt and the fd was happy to point out that the extra natwest overdraft facility has not had to be used as yet. which moves me on to the drug delivery tech/tropical drugs stuff etc. theres been interest from large pharmas and generic cos and all liked what they saw. however, they need phase 1 trial data and of course dpt cant afford to do this on its own (cost of approx £2m per trial). so partners are needed to move things along. same goes for sanitizers. re mrsa, theyve got a handcream which works but dont hold high hopes as nhs system a nightmare to deal with. work done on mosquito and crop stuff was said to be promising. so, my overall take was of upbeatness. and of a new lease of life in the company. theres the potential to do some serious growing on the cosmetics side and theres all the other/blue sky stuff in for free. if things work out over the next 12mth id have thought that a big re-rating was on the cards. im happy to hold. all the above imho. |
Posted at 08/1/2005 10:37 by desert_fox Mr Rex,The news about Neil Morley has been in the (semi) public arena for some time and has was also included in Blank Frank's post 156 above. In my opinion, this is a good move since the original Disperse directors have not made sufficient progress with commercialising the technology. Neil was only the company secretary and has not signalled any intentions to sell his stock. So I would not view this as a negative move at all. The futuire of this company is expanding EF using the original DPT technology as a sort of unique selling point. It is a shame about the lack of posts on this board. I think this is partly due to the share price being in the doldrums, partly about the lack of PI interest in this stock and partly because Blank Frank (one of the main posters on the Board) threw his toys out of the pram rather than agreeing to differ. However, I really think this stock is on the turn and I expect that the AGM will be the start of a steady climb upwards based upon solid progress with Vivo sales. |
Posted at 11/12/2004 10:54 by desert_fox Blank Frank,Please don't accuse me of being naive I have been around the block a few times and have been a LT holder of this stock since day 1. I was simply trying to point out that it is laughable to think that BigT20 is responsible for the movement in price of this stock. I guess he is responsible for the fall in the share price price since the days of £1.60 then? As Rambutan points out, you are making a fool of yourself. As a LT holder, I am not in the slightest bit bothered by the current SP, because to anyone who is a believer in the company, it provides an excellent opportunity to average down. I normally find that posters who are extremely defensive of negative posts and sensitive to daily movements in the share price are from the pump and dump stable. Whilst I am sure that you do not wish to be tarred with the same brush, please relax a bit and wait for the news flow. I still disagree with your views regarding licensing and have done my own extensive research. However, I really don't wish to debate this with you, because in the absence of any further information, it is just one mans view against anothers. I look forward to seeing the response you get when you ask the question at the AGM, assuming that you attend. The spat between you and BigT20 is absolutely tedious for everyone else. You have both made your points and nothing is going to change between now and the AGM so please let it drop. My view is that this bulletin board could be a lot more active, but many posters are frankly put off by the constant sniping backwards and forwards. I repeat that I believe BigT20 is positive about this company, but has reservations about one aspect of performance, so I think you are attacking the wrong person. Finally, in the spirit of Christmas and for the sanity of everyone else, can I PLEASE urge you to bury the hatchet with BigT20. I am sure that he would reciprocate. ____________________ Blank Frank - 10 Dec'04 - 19:01 - 146 of 146 As regards the share price movement - don't be so nieve Desert Fox ... this isn't a FTSE 100 company. One small sale can easily move the price on AIM, and one person's trading decisions can easily be influenced by what they read on a bulletin board: ergo, one person's posting can affect the share price. So, a spate of negative posting by BigT20 almost immediately followed by DPT share price falls is a coincidence? Don't be so sure. |
Posted at 08/12/2004 20:16 by blank frank In view of the constant negativity and partiality of BigT20 it's no wonder that investors are gaining a distorted view, and are considering leaving. Please be aware that I have a good idea of the identity of BigT20, which I will keep confidential, but will say that he is a notoriously negative person. The very fact that he apparently went to the results presentation (which he has not denied) and is too selfish &/or lazy to give one word of feedback speaks volumes for his mentality. [In contrast, I posted a very lengthy write-up of the July floatation presentation. ]The unique thing about DPT (for its valuation) is that it has a lot of jam tomorrow AND plenty of jam today, whereas normally you would have to make a choice. The important here and now things are:- * Regular Estee Lauder licensing income of c. £1M. p.a. * Successful launch of Elizabeth French's VIVO range, which should mean EF profits of c. £2M. in 2006. * Launch of new BBW product range, which could double Disperse's licensing income; and new Estee Lauder product launch. * The imminent Virgin Vie product launches. These things alone should give DPT millions of pounds of profit and good multi-bagger status within two or three years, even if none of the jam tomorrow starts to roll in. It's rather ironic that DPT would apparently be viewed more positively, and perhaps have a higher valuation, if it only had the here and now stuff, and the other possibilities didn't even exist, so that people couldn't worry about them not happening (soon enough)! So please don't go! B.F. P.S. DPT also owns 10% of K B Innovations Group, which stake alone, even ignoring all DPT's own technologies, could be worth very many times DPT's current capitalisation. |
Posted at 05/12/2004 18:14 by blank frank BigT20 - 2 Dec'04 - 04:47 - 127 of 130B.F. "It seems that you have an optimistic opinion regarding the poor / non performing licenses . I prefer to look at the facts as they are regarding these licenses ." BigT20, Why don't you also look at the facts re.:- * Regular Estee Lauder licensing income of c. £1M. p.a. * Successful launch of Elizabeth French's VIVO range, which should mean EF profits of c. £2M. in 2006. * Launch of new BBW product range, which could double Disperse's licensing income; and new Estee Lauder product launch. * The imminent Virgin Vie product launches. You appear to be completely ignoring all the good things that more than justify DPT's share price, and instead are flagging up things that haven't come to fruition yet, but which are not accorded any value by the share price in any case (which means all the more value to potentially be added later). B.F. |
Posted at 29/11/2004 19:43 by blank frank The 19/11/04 "Investors Chronicle", which tipped DPT as a buy, also contained an interesting article entitled "Exceptional Returns" which is also relevant to DPT.The IC's research suggests that firms with exceptional losses tend to beat the market:- " ... investing in shares of the 10 companies with the biggest negative one-off items [relative to their adjusted earnings] would also have made good returns. Overall, this strategy beat the market by an average of 7.5 per cent in the following 12-month period ... Hanging on to either group of shares for longer produces even better results. [Actually, average of 10.2% total outperformance over 3 years (i.e. not 10.2% p.a.).] ... The lessons here seem clear enough. While investors focus on the earnings figure and ignore the exceptionals, out findings suggest it would be better to concentrate on the exceptionals and ignore the earnings." High exceptional costs have reduced DPT's 2004 results. These should not recur, but I don't think that fact is yet being reflected in the share price. B.F. |
Posted at 22/11/2004 19:41 by blank frank Historic license revenues have clearly stalled over the last few years. But that doesn't necessarily reflect badly upon Disperse's technology: it's my observation that such licence revenue delays in general are the norm, rather than the exception - look at virtually any stockmarket company that licences its technology, and there are typically delays accompanied by a falling share price. Large corporates just can seem to take a long time in their decision-making and development. But I don't think that Shiseido America, Nu Skin, etc. signed those licences just for the fun of it.Disperse is below a tenth of its Ofex high to reflect the delays, and the current valuation isn't dependent upon any new licence revenue - that's not why the IC tipped it, as there's plenty of upside without that. So if and when new licence revenues do start do come on stream (which they may already have done with new Bath & Body Works product launches), that should be a bonus to the share price. B.F. |
Posted at 21/11/2004 18:29 by blank frank I.C.: "BEAR POINTS* Tech licensing business is low-margin" Low-margin? EDELIN - 14 Jan'03 - 15:11 - 50 of 74 "AGM Feedback ... Chairman quoted he forsees £M15 profit at £M25 turnover. ..." What the IC means, but has rather misleadingly put, is that DPT's slice (or margin) of the LICENCEE'S revenues is comparatively low. But these licencee revenues that come in to DPT are very HIGH margin for DPT - it may have to do little more than sit back and receive the money. And because the licencees can be such huge companies with sales in the hundreds of millions of dollars +, even a small cut can be quite a lot: i.e. c. £1M. p.a. income to DPT from Estee Lauder. In addition, Disperse is revising its licence agreement with Bath & Body Works: in broad terms, this will give Disperse a four-fold increase in revenues. I believe that this is the plan for other licencees too. Arguably therefore an IC bull point should be "tech licensing business is HIGH-margin" ... = 3 bull points, no bear points! That would certainly be the view that I would lean to. Of course, DPT has now broadened its types of income stream to include selling final packaged products to retailers (Elizabeth French products at present), and providing finished products to other companies to package (Virgin Vie initially). These will give DPT a higher share of the final product revenues, but lower average margins on its actual income, though still quite good. Having said all this, the IC buy tip is clearly fantastic news, as it will help to put DPT onto more radar screens - important, as it's still comparatively little known. DPT's only been on AIM for about four months, and with the flood of AIM floats this year it's easy to get widely overlooked. 'Copycat' tipping may follow in due course, as the IC is so influential ... in previous years Disperse has been tipped on Ofex (at far higher prices) by the Independent and the Telegraph, so they may now see it as legitimate to revisit it. Watch out for DPT nap tips at New Year. [Health tiddler Zi Medical (ZIM) was picked by the Mail on Sunday as a tip for 2004, and the shares immediately went through the roof - DPT looks far superior to ZIM in terms of both results and licensing.] And the IC itself follows its tips, and repeat tips them as appropriate. DPT certainly looks a good bet for this if existing progress is maintained. All of which is clearly good news for the long term, as a healthy share price will make it easier to make an additional acquisition with less dilution - e.g. a cash-'rich' pharmaceutical company, as was suggested at Disperse's 13/7/04 presentation. B.F. P.S. DPT should rise further tomorrow (Monday). IC tips usually do, because lots of people don't see it until Friday evening. And as a recent AIM new issue DPT will be newer to more people ... and, I believe, attractive to lots of people. |
Posted at 07/11/2004 16:43 by blank frank Tomorrow we enter the 'fifth dimension', as Disperse unveils its fifth set of final results since its 3/00 Ofex float. So, will it be a 'bunch of fives', or will we be 'high fiving' in delight? Just for fun, here are a few 'speculations' for Monday by myself. [DPT's last four LSE announcements have been out of market hours, so the results may well be announced before market opening].The fact that DPT's share price has edged up to 19.25p ahead of the results is clearly a good sign. In fact, looking at my Disperse Ofex chart, a similar thing has happened before each of the last three sets of finals, and in each case was the start of a swift (i.e. within about a week) jump of about 50% or more. Of course, on the LSE liquidity is greater than on Ofex, so it would take more buying to trigger such a rise; but equally, more people are willing to buy on the LSE than on Ofex, and also tend to buy in larger amounts. The recent Hoodless Brennan research note implied a second half DPT profit of c. £100K. (full year loss £0.4M.), which I believe would be great news. The fact that the note was published after the year end, with no downgrade, is encouraging. In addition, the interim turnover to 29/2/04 was better than the previous half year turnover to 31/8/03 ((£515K. v. £471K.), despite the weakened US$ in the more recent period; could this mean that new licensing income from product launches was starting to feed in towards the end of the last interim period, with a full second half contribution to follow? There's also the possibility of a bonus announcement with the results, or shortly afterwards. E.g. news on the second oral drug delivery test (results were expected in the summer), and (if successful) news on selling/licensing of that technology? The last new licence agreement was way back in March 2003, so we are certainly due another one, and previous such announcements helped Disperse to achieve multi bagger status in the past. Might we also see some more director share buying, but in the market this time, e.g. by the new Finance Director?! B.F. |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
